S-1/A: BrightSpring Health Services Eyes Public Market with Amended S-1 Filing

BrightSpring Health Services files an amended S-1 registration statement, signaling its intent to proceed with an initial public offering and a concurrent offering of tangible equity units.

Summary

• BrightSpring Health Services has filed an amended S-1 registration statement for a proposed offering of common stock.
• The company plans to list its common stock on the Nasdaq Global Select Market under the symbol BTSG.
• Concurrently, BrightSpring is offering tangible equity units through a separate prospectus.
• The closing of the unit offering is contingent upon the closing of the common stock offering.
• KKR and Walgreens Boots Alliance will collectively own approximately 67.9% of the voting power after the offering.
• BrightSpring intends to use the net proceeds from both offerings to repay debt and pay termination fees related to a monitoring agreement.
• Preliminary estimates for 2023 include revenue ranging from $8.7 billion to $8.8 billion and Adjusted EBITDA ranging from $530.0 million to $537.8 million.
• The company estimates a net loss ranging from $163.0 million to $157.5 million for the year ended December 31, 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights growth and strategic initiatives, it also acknowledges a net loss and significant debt. The overall tone is cautiously optimistic.

Positives

• The company is pursuing strategic growth initiatives through the IPO and concurrent unit offering.
• The company has a plan to reduce debt and associated interest expenses.
• The company has a plan to terminate a monitoring agreement and associated fees.
• The company has a plan to list on the Nasdaq Global Select Market.

Negatives

• The company estimates a net loss ranging from $163.0 million to $157.5 million for the year ended December 31, 2023.
• The company's closing of the unit offering is contingent on the closing of the common stock offering.
• The company's stock price may change significantly following this offering, and you may not be able to resell shares of our common stock at or above the price you paid or at all, and you could lose all or part of your investment as a result.

Risks

• The closing of the unit offering is contingent upon the closing of the common stock offering.
• The company estimates a net loss ranging from $163.0 million to $157.5 million for the year ended December 31, 2023.
• The company's stock price may change significantly following this offering, and you may not be able to resell shares of our common stock at or above the price you paid or at all, and you could lose all or part of your investment as a result.
• The company is controlled by KKR Stockholder and Walgreen Stockholder and their interests may conflict with yours in the future.
• The company will be a controlled company within the meaning of the rules of Nasdaq and the rules of the SEC and, as a result, qualify for, and intend to rely on, exemptions from certain corporate governance requirements.

Future Outlook

The company expects to continue to pursue and capitalize on growth opportunities in its existing core pharmacy and provider services.

Industry Context

The announcement reflects a broader trend of healthcare companies seeking public funding to fuel expansion and innovation in the growing home and community-based healthcare services market.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• However, the document does mention some competitors such as Option Care Health, Inc., Coram CVS/specialty infusion services, Accredo Health Group, Inc., Optum Specialty Pharmacy, Amedisys, Inc., Encompass Health Corporation, LHC Group, Inc., and Addus HomeCare Corporation.
• A detailed comparison would require a deeper dive into specific metrics and operational data.

Legal Proceedings

• The company agreed to settle the Silver matter without admitting liability.
• The estimated financial impact of the settlement is $115.0 million, which we accrued in the nine months ended September 30, 2023.

Related Party Transactions

• The company has a monitoring agreement with KKR and Walgreens Boots Alliance, which requires payment of an aggregate advisory fee equivalent to 1% of consolidated EBITDA.
• The company purchases pharmaceuticals through an agreement with Walgreens Boots Alliance and its affiliates.
• KKR Capital Markets LLC, an affiliate of KKR & Co., acted as an arranger and bookrunner for various financing transactions under the First Lien Facilities and the Second Lien Facility, and received underwriter and transaction fees totaling approximately $5.8 million and $2.5 million for the year ended December 31, 2021 and 2020, respectively, and $0 for each of the year ended December 31, 2022 and the nine months ended September 30, 2023.

Stakeholder Impact

• Shareholders will experience dilution as a result of the new share issuance.
• Employees may benefit from the company's continued growth and strategic initiatives.
• Customers and patients should see continued access to quality healthcare services.
• Creditors will be impacted by the company's debt repayment plans.

Next Steps

• The company needs to secure approval for its common stock and Units to be listed on Nasdaq.
• The company needs to successfully execute both the common stock offering and the tangible equity units offering.
• The company needs to effectively deploy the net proceeds to reduce debt and improve its financial position.

Key Dates

Keywords

initial public offering, common stock, tangible equity units, BrightSpring Health Services, KKR, Walgreens Boots Alliance, S-1, registration statement, debt repayment, financial metrics, healthcare services, pharmacy, provider